|
KMID : 0370220090530060357
|
|
Yakhak Hoeji
2009 Volume.53 No. 6 p.357 ~ p.367
|
|
|
Effects of Pioglitazone and Rosiglitazone on Glucose and the Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Meta-analysis
|
|
Lee Jae-Kyoung
Lee Eui-Kyung
|
|
|
Abstract
|
|
|
|
A meta-analysis of 63 randomized controlled trials of Pioglitazone and Rosiglitazone in patients with type 2 diabetes was conducted. Pioglitazone significantly lowered fasting plasma glucose and triglyceride (TG) level and increased high-density lipoprotein cholesterol (HDL) level. Rosiglitazone significantly lowered hemoglobin A1C level and fasting plasma glucose, whereas it increased all kinds of lipids (HDL, LDL (low-density lipoprotein cholesterol), TG, total cholesterol). In comparison, glucose lowering effect was higher in Rosiglitazone, and Pioglitazone produced a more favorable lipid profile.
|
|
|
KEYWORD
|
|
|
Pioglitazone, Rosiglitazone, type 2 diabetes, meta-analysis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|